Potential COVID-19 jab would apply to individuals age 12 and older
Pfizer and BioNTech have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted bivalent COVID-19 vaccine candidate, based on the BA.1 sub-lineage, for individuals 12 years of age and older.
The companies previously announced safety, tolerability, and immunogenicity data from a Phase 2/3 trial that found a 30 µg booster dose of the Omicron-adapted bivalent vaccine candidate produced a superior immune response against Omicron BA.1, as compared to the companies’ current COVID shot. The bivalent vaccine candidate was well-tolerated with a favorable safety profile.
The involved parties previously shared these data with FDA to support a potential variant-adapted vaccine, and they continue to submit additional data as advised by the agency.
Trending Data & Response Plans in the Cleanroom Setting
April 30th 2025Being proactive with and responsive to your environmental monitoring (EM) data helps prevent problems with cleanroom contamination. Learn more about EM and cleanroom best practices and to see how ABM can implement industry-leading cleanroom solutions for your facility.
ABM’s Digital Solution for Good Manufacturing Practices
April 30th 2025Learn how our digital GMP solution ensures compliance with high regulatory standards, and offers faster, more accurate data access. By utilizing a mobile app for data collection and a management dashboard for task visibility and validation, it goes beyond traditional paper methods to meet growing industry needs.